Ritholtz Wealth Management reduced its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 25.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 50,434 shares of the biopharmaceutical company’s stock after selling 17,654 shares during the period. Ritholtz Wealth Management’s holdings in Pfizer were worth $2,058,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Harbor Investment Advisory LLC grew its holdings in Pfizer by 3.6% in the fourth quarter. Harbor Investment Advisory LLC now owns 23,977 shares of the biopharmaceutical company’s stock valued at $1,229,000 after purchasing an additional 825 shares during the period. BancFirst Trust & Investment Management lifted its position in Pfizer by 2.3% during the first quarter. BancFirst Trust & Investment Management now owns 17,794 shares of the biopharmaceutical company’s stock worth $719,000 after buying an additional 398 shares in the last quarter. Secure Asset Management LLC lifted its position in Pfizer by 3.5% during the fourth quarter. Secure Asset Management LLC now owns 15,835 shares of the biopharmaceutical company’s stock worth $811,000 after buying an additional 537 shares in the last quarter. Range Financial Group LLC lifted its position in Pfizer by 2.8% during the first quarter. Range Financial Group LLC now owns 37,010 shares of the biopharmaceutical company’s stock worth $1,510,000 after buying an additional 1,024 shares in the last quarter. Finally, Allred Capital Management LLC raised its position in Pfizer by 1.9% in the fourth quarter. Allred Capital Management LLC now owns 20,425 shares of the biopharmaceutical company’s stock valued at $1,047,000 after purchasing an additional 387 shares during the period. 67.80% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
PFE has been the topic of a number of research analyst reports. Jefferies Financial Group initiated coverage on Pfizer in a research report on Monday, March 6th. They issued a “hold” rating and a $43.00 target price on the stock. Morgan Stanley reduced their target price on Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Monday, April 10th. StockNews.com downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday. Barclays reduced their target price on Pfizer from $43.00 to $40.00 in a research report on Wednesday, May 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Pfizer in a report on Wednesday, May 17th. Eleven analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $46.67.
Pfizer Price Performance
Shares of NYSE PFE opened at $36.68 on Monday. The stock’s 50-day moving average is $38.32 and its two-hundred day moving average is $42.05. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.37 and a quick ratio of 1.11. Pfizer Inc. has a 1-year low of $35.76 and a 1-year high of $54.93. The company has a market cap of $207.07 billion, a price-to-earnings ratio of 7.22, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61.
Pfizer (NYSE:PFE – Free Report) last issued its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.23. Pfizer had a return on equity of 37.53% and a net margin of 31.25%. The company had revenue of $18.28 billion for the quarter, compared to the consensus estimate of $16.49 billion. During the same quarter in the prior year, the business earned $1.62 EPS. Pfizer’s revenue was down 28.8% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 3.35 EPS for the current fiscal year.
Pfizer Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th will be issued a $0.41 dividend. The ex-dividend date is Thursday, July 27th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 4.47%. Pfizer’s payout ratio is currently 32.28%.
Insider Activity
In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction dated Monday, May 8th. The shares were acquired at an average price of $38.58 per share, for a total transaction of $38,580.00. Following the acquisition, the director now owns 6,000 shares in the company, valued at approximately $231,480. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.05% of the company’s stock.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.